Effectiveness and safety of TACROLIMUS (cas 109581-93-3) therapy for myasthenia gravis: A single arm meta-analysis

Add time:07/26/2019    Source:sciencedirect.com

To evaluate the effectiveness and safety of TACROLIMUS (cas 109581-93-3) in myasthenia gravis (MG) patients, a systematic review and meta-analysis was performed. Researches published between January 1, 2000 and December 31, 2017 in English language were searched in Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and clinicaltrials.gov databases. We extracted the outcome measures regarding the dose of glucocorticoids (GC), Myasthenia Gravis Foundation of America (MGFA) quantitative myasthenia gravis score (QMGS), MG activities of daily living (MG-ADL) and serum anti-acetylcholine receptor (AChR) antibody titer in each included study. Among 25 studies involving 633 patients, we observed a mean reduction in GC dose by 1.21 (95% CI, 0.44–1.98), QMGS by 2.02 (95% CI, 0.86–3.18), MG-ADL by 1.21 (95% CI, 0.81–1.62) and serum anti-AChR antibody titer by 0.61 (95% CI, 0.43–0.80), which all reached a statistical significance (p < 0.01). Interestingly, a significant correlation was acquired between the disease duration and the reduction of QMGS (p = 0.033; 95% CI, −0.64 to −0.033). Adverse events (AEs) were recorded in 258 of 633 patients (40.8%) with tacrolimus therapy while most were mild. Our meta-analysis demonstrates that tacrolimus may be a beneficial drug option to treat MG.

We also recommend Trading Suppliers and Manufacturers of TACROLIMUS (cas 109581-93-3). Pls Click Website Link as below: cas 109581-93-3 suppliers

Prev:Conversion From Immediate-Release TACROLIMUS (cas 109581-93-3) to Prolonged-Release TACROLIMUS (cas 109581-93-3) in Stable Heart Transplant Patients: A Retrospective Study
Next:Inhibitory effect of immunosuppressive drug TACROLIMUS (cas 109581-93-3) on voltage-gated K+ current in rabbit coronary arterial smooth muscle cells)